|
Variable
|
Median TTP (months)
|
P value
|
Median OS (months)
|
P value
|
|---|
|
Age (years)
| |
0.516
| |
0.609
|
|
≤50
|
10
| |
42
| |
|
>50
|
9
| |
36
| |
|
Menopausal status
| |
0.306
| |
0.076
|
|
Premenopausal
|
10
| |
45
| |
|
Postmenopausal
|
10
| |
37
| |
|
KPS score
| |
0.916
| |
0.039a
|
|
70–80
|
8
| |
33
| |
|
90–100
|
8
| |
44
| |
|
DFS (years)
| |
0.670
| |
0.077
|
|
≤2
|
10
| |
34
| |
|
>2
|
8
| |
43
| |
|
No. of metastases
| |
0.081
| |
0.114
|
|
≤1
|
14
| |
55
| |
|
>1
|
9
| |
36
| |
|
Site of metastases
| | | | |
|
Viscera
|
9
|
0.106
|
41
|
0.905
|
|
Non-viscera
|
13
| |
42
| |
|
Response to FCCT
| |
0.883
| |
0.337
|
|
SD
|
10
| |
41
| |
|
CR + PR
|
10
| |
43
| |
-
TTP time-to-progression, OS overall survival, KPS Karnofsky performance status, CR complete response, PR partial response, SD stable disease, DFS disease-free survival, CT chemotherapy, FCCT first-line capecitabine-based combination chemotherapy
-
aSince there were only 36 patients in the group whose KPS score was 70-80, no conclusions could be drawn from the log-rank analysis of OS
